1/20
Vocabulary practice flashcards covering the components, mechanisms, comparative pathways, and experimental perturbations of the angiotensin II phosphoinositide signaling pathway.
Angiotensin II
The hormone that uses the phosphoinositide pathway to cause vasoconstriction, which regulates (raises) blood pressure.
Vascular smooth muscle cells
The cell type in blood vessel walls where the angiotensin II pathway acts.
Phosphatidylinositol 4,5-bisphosphate (PIP2)
A phospholipid located in the plasma membrane that is cut by phospholipase C into the second messengers IP3 and DAG.
Phospholipase C
The enzyme activated through a G protein upon hormone receptor binding that cuts PIP2 into IP3 and DAG.
Inositol 1,4,5-trisphosphate (IP3)
A second messenger released into the cytoplasm that diffuses to the smooth ER and opens Ca2+ channels in the ER membrane.
Diacylglycerol (DAG)
A second messenger that remains in the plasma membrane after cleavage of PIP2 and helps activate protein kinase C.
Protein kinase C (PKC)
A kinase activated by DAG in the membrane together with Ca2+ released by IP3, which causes vasoconstriction (smooth muscle contraction).
Vasoconstriction
Smooth muscle contraction in blood vessel walls caused by PKC activation that regulates (raises) blood pressure.
Smooth endoplasmic reticulum
The organelle whose lumen stores Ca2+ at high concentration before release by IP3.
IP3-gated Ca2+ release
A process of passive transport (facilitated diffusion) where Ca2+ flows down its concentration gradient through a ligand-gated channel without ATP.
Protein kinase A (PKA)
The kinase associated with cAMP in the epinephrine signaling pathway (remembered by 'A' for AMP).
Epinephrine pathway
A GPCR signaling pathway that proceeds through adenylyl cyclase → cAMP → PKA.
Angiotensin II pathway
A GPCR signaling pathway that proceeds through phospholipase C → IP3 + DAG (+ Ca2+) → PKC.
Phospholipase C inhibition
A condition in which PIP2 is not cleaved, preventing the production of IP3 and DAG, blocking Ca2+ release, leaving PKC inactive, and preventing vasoconstriction.
ER Ca2+ channel binding defect
A defect preventing IP3 from binding its channel; receptor activation, phospholipase C, and IP3/DAG production still occur, but Ca2+ release fails, preventing full PKC activation and vasoconstriction.
PKC inhibitor
A compound under which upstream steps function normally (IP3 and Ca2+ levels still rise), but blood vessels do not constrict because PKC cannot act.
Angiotensin II receptor blocker
A drug that causes blood pressure to drop by halting receptor activation, thereby preventing the phospholipase C → IP3/DAG → Ca2+ → PKC cascade so vessels constrict less.
G protein
The signaling protein that is activated immediately following angiotensin II receptor binding and subsequently activates phospholipase C.
Cytoplasm
The intracellular fluid compartment where IP3 is released after cleavage and into which Ca2+ flows from the ER lumen.
Ligand-gated Ca2+ channel
The membrane channel on the smooth ER that opens when bound by the ligand IP3, allowing passive diffusion of calcium ions.
Second messengers
Intracellular signaling molecules produced during signal transduction, specifically IP3 and DAG in the phosphoinositide pathway, and cAMP in the epinephrine pathway.